Literature DB >> 19326065

[Quadsparing approach in total knee arthroplasty].

David Wohlrab1, Alexander Zeh, Thomas Mendel, Werner Hein.   

Abstract

OBJECTIVE: Approach to the knee joint for total knee arthroplasty (TKA) with gentle soft-tissue handling. INDICATIONS: Primary TKA with range of motion>or=100 degrees, leg axis up to 10 degrees varus or valgus, body weight<100 kg. CONTRAINDICATIONS: Contracted knees, leg axis>10 degrees varus or valgus, obesity, previous knee surgery except arthroscopic procedures, rheumatoid arthritis. SURGICAL TECHNIQUE: Anterior midline incision. Soft-tissue preparation and capsule incision start at the upper tip of the patella and are continued distally along the medial patellar border ending at the tibial tuberosity. After opening of the joint, the patella is dislocated laterally without everting it. Exposure of the articular surface using a "mobile window". Preparation and insertion of the TKA components using special instruments. Wound closure in layers. POSTOPERATIVE MANAGEMENT: Mobilization on crutches with full weight bearing starting on the day of surgery. Daily medical training therapy. Passive motion therapy continued twice a day. Low-dose heparin s.c. for 35 days after surgery.
RESULTS: In a prospective randomized clinical study, 50 patients with a quadsparing (QS) approach were observed up to 3 months after surgery. In three patients, the use of large femoral components required an extended approach. During the hospital stay knee flexion was significantly greater in patients with the QS approach than in patients with the standard procedure (midvastus approach). There were no differences in implant positioning, Knee Society Score and complication rate between both groups. Use of the QS approach prolonged the duration of surgery by 25 min.

Entities:  

Mesh:

Year:  2009        PMID: 19326065     DOI: 10.1007/s00064-009-1603-0

Source DB:  PubMed          Journal:  Oper Orthop Traumatol        ISSN: 0934-6694            Impact factor:   1.154


  13 in total

1.  Minimally invasive quadriceps-sparing TKA: results of a comprehensive pathway for outpatient TKA.

Authors:  Richard A Berger; Sheila Sanders; Eileen D'Ambrogio; Kate Buchheit; Carl Deirmengian; Wayne Paprosky; Craig J Della Valle; Aaron G Rosenberg
Journal:  J Knee Surg       Date:  2006-04       Impact factor: 2.757

2.  Anatomy of the extensor mechanism in reference to quadriceps-sparing TKA.

Authors:  Mark W Pagnano; R Michael Meneghini; Robert T Trousdale
Journal:  Clin Orthop Relat Res       Date:  2006-11       Impact factor: 4.176

Review 3.  Specialized instruments and modular implants for minimally invasive total knee arthroplasty.

Authors:  Thomas M Coon
Journal:  Am J Orthop (Belle Mead NJ)       Date:  2006-07

Review 4.  Minimally invasive total knee arthroplasty: surgical technique.

Authors:  Giles R Scuderi
Journal:  Am J Orthop (Belle Mead NJ)       Date:  2006-07

Review 5.  Minimally invasive approaches to total knee arthroplasty: results.

Authors:  Jess H Lonner
Journal:  Am J Orthop (Belle Mead NJ)       Date:  2006-07

6.  Quadriceps sparing total knee replacement. The initial experience with results at two to four years.

Authors:  A F Chen; R K Alan; D E Redziniak; A J Tria
Journal:  J Bone Joint Surg Br       Date:  2006-11

7.  [Quadriceps-sparing minimally invasive technique for total knee arthroplasty : a new classification].

Authors:  T M Coon
Journal:  Orthopade       Date:  2007-12       Impact factor: 1.087

8.  Quadriceps-sparing total knee arthroplasty using the posterior stabilized TKA design.

Authors:  Rodney K Alan; Alfred J Tria
Journal:  J Knee Surg       Date:  2006-01       Impact factor: 2.757

9.  [Influence of the surgical approach on postoperative rehabilitation after TKA].

Authors:  D Wohlrab; N Gutteck; M Hildebrand; A Zeh; W Hein
Journal:  Z Orthop Unfall       Date:  2008 Mar-Apr       Impact factor: 0.923

10.  Minimal incision total knee arthroplasty: early experience.

Authors:  Alfred J Tria; Thomas M Coon
Journal:  Clin Orthop Relat Res       Date:  2003-11       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.